Market overview
The global multi-organ transplant monitoring market is worth USD 1.1 bn in 2026 and is forecast to reach USD 2.5 bn by 2036, growing at a 9.0% CAGR. United States is the largest country market and Donor-derived cell-free DNA is the largest by test segment.
| Scope | Tests used to watch for rejection and infection after solid organ transplants: donor-derived cell-free DNA, gene-expression profiles, viral load tests for CMV, BK and EBV, and immune function assays. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 980 mn |
| Value 2026 | USD 1.1 bn |
| Value 2036 | USD 2.5 bn |
| CAGR 2026-2036 | 9.0% |
| Volume 2026 | 2,071 thousand tests |
| Volume 2036 | 4,903 thousand tests |
| Average price 2026 | USD 516 per test |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Multi-Organ Transplant Monitoring market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 1.1 bn |
| 2027 | USD 1.2 bn |
| 2028 | USD 1.3 bn |
| 2029 | USD 1.4 bn |
| 2030 | USD 1.5 bn |
| 2031 | USD 1.6 bn |
| 2032 | USD 1.8 bn |
| 2033 | USD 2.0 bn |
| 2034 | USD 2.1 bn |
| 2035 | USD 2.3 bn |
| 2036 | USD 2.5 bn |
Multi-Organ Transplant Monitoring market segmentation
By test
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Donor-derived cell-free DNA | 43.0% | 46.3% | USD 459 mn | 9.8% |
| Viral load monitoring | 33.0% | 28.3% | USD 353 mn | 7.3% |
| Immune function and biomarker assays | 16.0% | 18.9% | USD 171 mn | 10.8% |
| Gene-expression profiling | 8.0% | 6.5% | USD 85 mn | 6.8% |
By organ
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Kidney | 52.0% | 51.5% | USD 555 mn | 8.9% |
| Heart | 18.0% | 18.7% | USD 192 mn | 9.4% |
| Lung | 12.0% | 13.0% | USD 128 mn | 9.9% |
| Liver | 12.0% | 11.4% | USD 128 mn | 8.4% |
| Other organs | 6.0% | 5.4% | USD 64 mn | 7.9% |
By technology
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Donor-derived cell-free DNA | 36.0% | 38.0% | USD 385 mn | 9.6% |
| Gene expression profiling | 28.0% | 29.0% | USD 299 mn | 9.4% |
| Immunoassays and biochemistry | 22.0% | 19.0% | USD 235 mn | 7.4% |
| Microbiome and viral monitoring | 14.0% | 14.0% | USD 150 mn | 9.0% |
By end user
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Transplant centers | 52.0% | 48.0% | USD 555 mn | 8.1% |
| Reference laboratories | 30.0% | 31.0% | USD 320 mn | 9.4% |
| Home and decentralized monitoring | 18.0% | 21.0% | USD 192 mn | 10.7% |
By monitoring phase
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Pre-transplant matching | 18.0% | 16.0% | USD 192 mn | 7.7% |
| Early post-transplant | 34.0% | 32.0% | USD 363 mn | 8.3% |
| Long-term surveillance | 48.0% | 52.0% | USD 513 mn | 9.9% |
Top 25 countries for multi-organ transplant monitoring by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 92.0% of 2026 revenue and the 25 countries below together hold 97.8%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 620 mn | 58.0% | USD 1.5 bn | 9.3% |
| 2 | Germany | USD 64 mn | 6.0% | USD 142 mn | 8.2% |
| 3 | United Kingdom | USD 53 mn | 5.0% | USD 124 mn | 8.8% |
| 4 | France | USD 53 mn | 5.0% | USD 119 mn | 8.3% |
| 5 | Japan | USD 43 mn | 4.0% | USD 91 mn | 7.9% |
| 6 | Canada | USD 32 mn | 3.0% | USD 73 mn | 8.6% |
| 7 | Australia | USD 32 mn | 3.0% | USD 78 mn | 9.4% |
| 8 | Spain | USD 32 mn | 3.0% | USD 71 mn | 8.2% |
| 9 | Italy | USD 32 mn | 3.0% | USD 68 mn | 7.9% |
| 10 | Brazil | USD 21 mn | 2.0% | USD 56 mn | 10.0% |
| 11 | Netherlands | USD 12 mn | 1.1% | USD 28 mn | 9.2% |
| 12 | South Korea | USD 9.2 mn | 0.9% | USD 22 mn | 9.2% |
| 13 | Belgium | USD 7.9 mn | 0.7% | USD 19 mn | 9.3% |
| 14 | Switzerland | USD 6.3 mn | 0.6% | USD 15 mn | 9.4% |
| 15 | Austria | USD 5.5 mn | 0.5% | USD 13 mn | 9.2% |
| 16 | Sweden | USD 4.4 mn | 0.4% | USD 11 mn | 9.3% |
| 17 | Denmark | USD 3.5 mn | 0.3% | USD 8.3 mn | 9.0% |
| 18 | Mexico | USD 2.9 mn | 0.3% | USD 7.1 mn | 9.4% |
| 19 | Israel | USD 2.4 mn | 0.2% | USD 5.8 mn | 9.5% |
| 20 | Poland | USD 2.0 mn | 0.2% | USD 4.8 mn | 9.0% |
| 21 | Turkey | USD 1.6 mn | 0.1% | USD 4.0 mn | 9.7% |
| 22 | Norway | USD 1.4 mn | 0.1% | USD 3.3 mn | 9.0% |
| 23 | India | USD 1.2 mn | 0.1% | USD 3.0 mn | 9.9% |
| 24 | Argentina | USD 0.96 mn | 0.09% | USD 2.3 mn | 9.0% |
| 25 | Saudi Arabia | USD 0.85 mn | 0.08% | USD 2.0 mn | 9.0% |
| Rest of world | USD 24 mn | 2.2% | USD 56 mn | 8.8% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- CareDx
- Natera
- Roche Diagnostics
- Abbott
- Thermo Fisher Scientific
Group 2: Regional and specialist players
- Eurofins Viracor
- Qiagen
- Immucor
- DiaSorin
- Hologic
Group 3: Emerging and niche players
- Verici Dx
- Oncocyte
- GenDx
- Omixon
- Chronix Biomedical
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the multi-organ transplant monitoring market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 9.0% is calculated from the resulting values.
The market is divided by test, by organ, by technology, by end user, by monitoring phase. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the multi-organ transplant monitoring market?
The global multi-organ transplant monitoring market is estimated at USD 980 mn in 2025 and USD 1.1 bn in 2026.
How fast will the multi-organ transplant monitoring market grow?
It is forecast to reach USD 2.5 bn by 2036, a compound annual growth rate of 9.0% from 2026, an increase of USD 1.5 bn.
Which country is the largest market for multi-organ transplant monitoring?
United States is the largest market by revenue at USD 620 mn in 2026, 58.0% of the global total. The three largest countries together hold 69.0%.
Which country is growing fastest?
Among the ten largest markets, Brazil is growing fastest at 10.0% a year from 2026 to 2036.
Which multi-organ transplant monitoring segment is largest?
In the by test split, Donor-derived cell-free DNA is the largest segment with 43.0% of 2026 revenue.
Who are the leading multi-organ transplant monitoring companies?
Global leaders include CareDx, Natera, Roche Diagnostics, Abbott.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Urology Ablation DevicesUSD 1.1 bn · 10.0% CAGR
- AmpouleUSD 1.0 bn · 3.6% CAGR
- Hospital Capacity Management SolutionsUSD 1.0 bn · 11.0% CAGR
- Endoscopic Imaging Logistics And ServiceUSD 1.0 bn · 5.5% CAGR
- Catheter-Based Pulmonary Embolism ThrombectomyUSD 1.1 bn · 12.0% CAGR
- Wearable InjectorUSD 1.1 bn · 13.0% CAGR
- Oncology Biomarker Translation ServicesUSD 990 mn · 9.5% CAGR
- Microwave Ablation DevicesUSD 1.2 bn · 9.5% CAGR